Bulk is a Determinant of Oxymetazoline Affinity for the ?1A-Adrenergic Receptor

2004 ◽  
Vol 10 (3-4) ◽  
pp. 109-116 ◽  
Author(s):  
Dan McCune ◽  
Robert Gaivin ◽  
Boyd Rorabaugh ◽  
Dianne Perez
Keyword(s):  
2020 ◽  
Author(s):  
Charles A. Williams ◽  
Kimberly E. Miller ◽  
Nisa P. Williams ◽  
Christine V. Portfors ◽  
David J. Perkel

Author(s):  
Daniel Morris ◽  
Debra Schwinn ◽  
Gregory Michelotti

1987 ◽  
Vol 58 (03) ◽  
pp. 834-838
Author(s):  
Knut Lande ◽  
Sverre Erik Kjeldsen ◽  
Ivar Eide ◽  
Paul Leren ◽  
Knut Gjesdal

SummaryBlood platelet function was evaluated in 10 men, all 50 years old, with untreated, mild hypertension. Each patient was examined four times: At the beginning of the study, after 5 weeks on placebo treatment, after the following 5 weeks on propranolol 160 mg daily, and finally after a second period of 5 weeks on placebo. At baseline the plasma level of the platelet release product (β-thromboglobulin (BTG) was 41.6 (30.5-57.0) μg/l (median and 95% confidence interval). During the first placebo period BTG was normalized to 21.0 (14.1-25.9) μg/l. While systolic blood pressure and heart rate fell during β-adrenergic receptor blockade, BTG remained unchanged throughout the rest of the observation periods. Platelet size increased significantly during treatment with β-blocker. The present study indicates that the normalization of elevated platelet function which previously has been reported to occur during anti-hypertensive drug therapy, may be explained by patient adaptation to the blood sampling procedure.


1970 ◽  
Vol 23 (03) ◽  
pp. 417-422 ◽  
Author(s):  
D. G McKay ◽  
J.-G Latour ◽  
Mary H. Parrish

SummaryThe infusion of epinephrine in high doses produces disseminated intravascular coagulation by activation of Hageman factor. The effect is blocked by phenoxybenz-amine and is therefore due to stimulation of α-adrenergic receptor sites.


Sign in / Sign up

Export Citation Format

Share Document